Pharmaceuticals, Biotechnology and Life Sciences
Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 millionNEW YORK,…
-New testing method highlights link between protofibrils and biomarkers for neurodegeneration–Patient and caregiver perspectives on five-year treatment with lecanemab —…
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
PRINCETON, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that…
SUNNYVALE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human…
WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in 1Q 2025; new preclinical data for…
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) — Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a…
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company…
– Findings underscore that the combination of onvansertib with FOLFIRI and bevacizumab demonstrates clinical activity and is well tolerated in…
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its third quarter…